Information  X 
Enter a valid email address

Summit Therapeutics PLC Ord 1P (SUMM)

Date Time Source Announcement
05 Sep 2019 12:00 pm
GNW
Summit Presented In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotics at ASM/ESCMID Conference
04 Sep 2019 12:00 pm
GNW
Summit Therapeutics to Participate in Upcoming Investor Conferences
01 Aug 2019 12:00 pm
GNW
Summit Therapeutics to Present at the Canaccord Genuity Growth Conference
17 Jul 2019 12:00 pm
GNW
Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress
09 Jul 2019 12:00 pm
GNW
Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia
20 Jun 2019 12:00 pm
GNW
Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019
19 Jun 2019 12:00 pm
GNW
Result of AGM
18 Jun 2019 12:00 pm
GNW
Increased BARDA Award and Option Exercise
12 Jun 2019 12:00 pm
GNW
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019
05 Jun 2019 2:00 pm
GNW
Notice of First Quarter Results
14 May 2019 5:30 pm
GNW
UK Annual Report and Notice of AGM
29 Apr 2019 12:30 pm
GNW
Block Listing Interim Review
24 Apr 2019 4:20 pm
GNW
Exercise of Restricted Stock Units
15 Apr 2019 7:00 am
GNW
Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
03 Apr 2019 12:00 pm
GNW
Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae
02 Apr 2019 12:00 pm
GNW
Summit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences Conference
29 Mar 2019 5:45 pm
GNW
Award of Share Options
  11:15 am
GNW
Filing of Annual Report on Form 20-F
27 Mar 2019 11:00 am
GNW
Final Results
25 Mar 2019 11:00 am
GNW
Notice of Results
18 Mar 2019 11:00 am
GNW
Summit Therapeutics to Present at Upcoming Conferences
14 Mar 2019 11:00 am
GNW
Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference
25 Feb 2019 12:00 pm
GNW
Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data
13 Feb 2019 12:00 pm
GNW
Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection
08 Feb 2019 12:00 pm
GNW
Summit Therapeutics to Present at the BIO CEO & Investor Conference
15 Jan 2019 5:45 pm
GNW
Holding(s) in Company
14 Jan 2019 12:00 pm
GNW
Award of Restricted Stock Units
10 Jan 2019 4:15 pm
GNW
Holding(s) in Company
  11:30 am
GNW
Holding(s) in Company
  7:00 am
GNW
Completion of $25 million Subscription
09 Jan 2019 4:45 pm
GNW
Holding(s) in Company
08 Jan 2019 7:00 am
GNW
Update on Admission
04 Jan 2019 12:30 pm
GNW
Result of General Meeting
02 Jan 2019 9:40 am
GNW
Holding(s) in Company
18 Dec 2018 12:15 pm
GNW
Holding(s) in Company
17 Dec 2018 7:05 am
GNW
Proposed Subscription to Raise $25m and Notice of General Meeting
  7:00 am
GNW
Summit Therapeutics Announces Departure of Chief Financial Officer
11 Dec 2018 12:00 pm
GNW
3rd Quarter Results
06 Dec 2018 12:00 pm
GNW
Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 on 11 December 2018
30 Nov 2018 1:30 pm
GNW
Holding(s) in Company
12 Nov 2018 12:00 pm
GNW
Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week
  7:00 am
GNW
Appointment of Joint Broker
07 Nov 2018 12:00 pm
GNW
Summit Therapeutics to Participate in Jefferies 2018 London Healthcare Conference
01 Nov 2018 4:34 pm
GNW
Holding(s) in Company
  11:00 am
GNW
Summit Recognises C. difficile Awareness Month
24 Oct 2018 4:15 pm
GNW
Director/PDMR Shareholding
22 Oct 2018 7:00 am
GNW
Award of Share Options
10 Oct 2018 12:00 pm
GNW
Summit Therapeutics to Participate in Upcoming Investor Events
08 Oct 2018 7:00 am
GNW
Surrender of Share Options
03 Oct 2018 12:00 pm
GNW
Summit Highlights Phase 3-Ready Precision Antibiotic Ridinilazole at IDWeek 2018
01 Oct 2018 3:00 pm
GNW
Block listing Interim Review
26 Sep 2018 12:00 pm
GNW
Summit to Highlight Potential of Precision Antibiotic Ridinilazole to Treat C. difficile Infection and Reduce Recurrent Disease at ID Week 2018
20 Sep 2018 12:00 pm
GNW
Summit Reports Financial Results for the Second Quarter Ended 31 July 2018 and Operational Progress
14 Sep 2018 12:00 pm
GNW
Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2018 on 20 September 2018
  12:00 pm
GNW
Summit Therapeutics to Participate in Upcoming Investor Conferences
06 Sep 2018 12:00 pm
GNW
Summit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets
05 Sep 2018 12:00 pm
GNW
Summit Nominates New Mechanism Antibiotic SMT-571 as its Lead Clinical Candidate for the Treatment of Gonorrhoea
03 Sep 2018 11:00 am
GNW
Total voting rights
29 Aug 2018 12:00 pm
GNW
Summit Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
16 Aug 2018 12:00 pm
GNW
Summit Awarded Additional $12 Million by BARDA for Ridinilazole
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t